MIM
CHRS icon

MetLife Investment Management’s Coherus Oncology CHRS Stock Holding History

MetLife Investment Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$65.9K Buy
+39,013
New +$69.3K ﹤0.01% 2648
2025
Q4 		– Sell
-63,678
Closed -$104K – 2823
2025
Q3 		$104K Buy
+63,678
New +$70.8K ﹤0.01% 2633
2025
Q1 		– Sell
-73,099
Closed -$101K – 2791
2024
Q4 		$101K Buy
+73,099
New +$82K ﹤0.01% 2621
2024
Q3 		– Sell
-62,706
Closed -$108K – 2857
2024
Q2 		$108K Buy
62,706
+8,552
+16% +$17.2K ﹤0.01% 2566
2024
Q1 		$129K Buy
54,154
+1,024
+2% +$2.52K ﹤0.01% 2419
2023
Q4 		$177K Hold
53,130
– – ﹤0.01% 2301
2023
Q3 		$199K Buy
53,130
+14,239
+37% +$65.8K ﹤0.01% 2213
2023
Q2 		$166K Hold
38,891
– – ﹤0.01% 2388
2023
Q1 		$266K Hold
38,891
– – ﹤0.01% 2051
2022
Q4 		$308K Hold
38,891
– – ﹤0.01% 1966
2022
Q3 		$374K Buy
38,891
+4,003
+11% +$40.5K ﹤0.01% 1848
2022
Q2 		$253K Hold
34,888
– – ﹤0.01% 2148
2022
Q1 		$450K Buy
34,888
+13,564
+64% +$172K ﹤0.01% 1839
2021
Q4 		$340K Hold
21,324
– – ﹤0.01% 1727
2021
Q3 		$343K Hold
21,324
– – ﹤0.01% 1753
2021
Q2 		$295K Hold
21,324
– – ﹤0.01% 1901
2021
Q1 		$312K Sell
21,324
-7,082
-25% -$120K ﹤0.01% 1793
2020
Q4 		$494K Hold
28,406
– – ﹤0.01% 1505
2020
Q3 		$521K Hold
28,406
– – 0.01% 1349
2020
Q2 		$507K Hold
28,406
– – 0.01% 1369
2020
Q1 		$461K Hold
28,406
– – 0.01% 1261
2019
Q4 		$511K Hold
28,406
– – 0.01% 1451
2019
Q3 		$576K Buy
28,406
+5,934
+26% +$119K 0.01% 1342
2019
Q2 		$497K Hold
22,472
– – 0.01% 1484
2019
Q1 		$307K Hold
22,472
– – ﹤0.01% 1742
2018
Q4 		$203K Hold
22,472
– – ﹤0.01% 1900
2018
Q3 		$371K Buy
+22,472
New +$398K ﹤0.01% 1724

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

MetLife Investment Management's CHRS Position: Q1 2026 in Review

MetLife Investment Management opened a new position in Coherus Oncology (CHRS) in Q1 2026: 39,013 shares worth $65.9K. The stake represents ﹤0.01% of the portfolio and ranks #2648 among its holdings. This is a return to the name: MetLife Investment Management previously reported a position in CHRS as recently as Q3 2025.

MetLife Investment Management first reported a position in CHRS in Q3 2018 and has held it in 27 quarters since. The position peaked at $576K in Q3 2019. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • MetLife Investment Management held 39,013 shares of Coherus Oncology worth $65.9K as of Q1 2026.
  • Coherus Oncology was a new MetLife Investment Management position in Q1 2026.
  • Coherus Oncology made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2648 holding.
  • MetLife Investment Management first reported a position in Coherus Oncology in Q3 2018 and has held it in 27 quarters since.
  • MetLife Investment Management's Coherus Oncology position peaked at $576K in Q3 2019.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.